| Literature DB >> 32582923 |
Agatheeswaran Subramaniam1, Kristijonas Žemaitis1, Mehrnaz Safaee Talkhoncheh1, David Yudovich1, Alexandra Bäckström1, Shubhranshu Debnath1, Jun Chen1, Mayur Vilas Jain1, Roman Galeev1, Massimiliano Gaetani2,3, Roman A Zubarev2,3, Jonas Larsson1.
Abstract
Culture conditions in which hematopoietic stem cells (HSCs) can be expanded for clinical benefit are highly sought after. Here, we report that inhibition of the epigenetic regulator lysine-specific histone demethylase 1A (LSD1) induces a rapid expansion of human cord blood-derived CD34+ cells and promotes in vitro propagation of long-term repopulating HSCs by preventing differentiation. The phenotype and molecular characteristics of cells treated with LSD1 inhibitors were highly similar to cells treated with UM171, an agent promoting expansion of HSCs through undefined mechanisms and currently being tested in clinical trials. Strikingly, we found that LSD1, as well as other members of the LSD1-containing chromatin remodeling complex CoREST, is rapidly polyubiquitinated and degraded upon UM171 treatment. CRISPR (clustered regularly interspaced short palindromic repeats)/Cas9 depletion of the CoREST core member, RCOR1, resulted in expansion of CD34+ cells similar to LSD1 inhibition and UM171. Taken together, LSD1 and CoREST restrict HSC expansion and are principal targets of UM171, forming a mechanistic basis for the HSC-promoting activity of UM171.Entities:
Mesh:
Substances:
Year: 2020 PMID: 32582923 PMCID: PMC7645986 DOI: 10.1182/blood.2020005827
Source DB: PubMed Journal: Blood ISSN: 0006-4971 Impact factor: 22.113